GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
59.00
-0.14 (-0.24%)
At close: May 12, 2025, 4:00 PM
61.12
+2.12 (3.59%)
After-hours: May 12, 2025, 7:53 PM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $87.12M in the quarter ending March 31, 2025, with 39.56% growth. This brings the company's revenue in the last twelve months to $330.14M, up 48.81% year-over-year. In the year 2024, GeneDx Holdings had annual revenue of $305.45M with 50.79% growth.
Revenue (ttm)
$330.14M
Revenue Growth
+48.81%
P/S Ratio
4.90
Revenue / Employee
$330,143
Employees
1,000
Market Cap
1.68B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
WGS News
- 5 days ago - GeneDx Announces Completion of Fabric Genomics Acquisition - Business Wire
- 12 days ago - GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - GeneDx Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 14 days ago - GeneDx: Strengthening Leadership In Genomic Diagnostics - Seeking Alpha
- 26 days ago - GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale - Business Wire
- 4 weeks ago - GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025 - Business Wire
- 5 weeks ago - GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication - Business Wire
- 7 weeks ago - GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire